By employing 1-(1H-indol-1-yl) ethanone as a scaffold, Xu and colleagues prepared a variety of innovative anti-prostate cancer CBP/p300 inhibitors (Fig. 10c), of which the representative compounds are 158 to 161. Y08175 (158) displays a twofold superior CBP binding than that of 149, with an IC50 of 37 nM, however this compound was shown ineffective in cellular assays [193]. The gene discussed is CREBBP; the disease is prostate carcinoma.